Perioperative coagulation management in cardiac surgery patients on treatment with direct oral anticoagulants, including assessment of residual anticoagulant effects of factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitors (dabigatran) in the context of cardiopulmonary bypass.
Conditions
Interventions
Group 1: Adult cardiac surgery patients (=18 years) with intake of direct oral anticoagulants (DOAC) receiving routine clinical care at University Hospital Bonn.
Within the established perioperative c
Sponsors
Universitätsklinikum Bonn, Klinik für Anästhesiologie und Operative Intensivmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age = 18 years, Performance of cardiac surgery, performance of viscoelastic and coagulation testing as part of routine clinical practice, use of DOACs
Exclusion criteria
Exclusion criteria: No Multiclot or coagulation testing performed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation coefficient (Pearson or Spearman, depending on the assumption of distribution) between the measurements from the Multiclot ECA/RVV test and the serum DOAK levels determined by laboratory analysis. Bland-Altman analysis to determine the mean deviation (bias) and the limits of agreement (LoA = bias ± 1.96 SD) between the two measurement methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| Descriptive analysis of supplementary diagnostic information using Multiclot | — |
Countries
Germany
Contacts
Public ContactFlorian Piekarski
Universitätsklinikum Bonn, Klinik für Anästhesiologie und Operative Intensivmedizin
Outcome results
None listed